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Abstract 1-Methyl-1,2,3,4-tetrahydroisoquinoline (1Me-
TIQ) is present in the human and rodent brain as a mixture
of stereospeciﬁc (R)- and (S)-1MeTIQ enantiomers. The
racemate, (R,S)-1MeTIQ, exhibits neuroprotective activity
as shown in the earlier study by the authors, and In addi-
tion, it was suggested to play a crucial physiological role in
the mammalian brain as an endogenous regulator of
dopaminergic activity. In this article, we investigated
the inﬂuence of stereospeciﬁc enantiomers of 1MeTIQ,
(R)- and (S)-1MeTIQ (50 mg/kg i.p.) on rotenone-induced
(3 mg/kg s.c.) behavioral and neurochemical changes in
the rat. In behavioral study, in order to record dynamic
motor function of rats, we measured locomotor activity
using automated locomotor activity boxes. In biochemical
studies, we analyzed in rat striatum the concentration of
dopamine (DA) and its metabolites: intraneuronal DOPAC,
extraneuronal 3-MT, and ﬁnal HVA using HPLC with
electrochemical detection. Otherwise, DA release was
estimated by in vivo microdialysis study. The behavioral
study has demonstrated that both acute and repeated
(3 times) rotenone administration unimportantly depressed
a basic locomotor activity in rat. (R)- and (S)-1MeTIQ
stereoisomers (50 mg/kg i.p.) produced a modest behav-
ioral activation both in naı ¨ve and rotenone-treated rats.
The data from ex vivo neurochemical experiments have
shown stereospeciﬁcity of 1MeTIQ enantiomers in respect
of their effectson DA catabolism. (R)-1MeTIQsigniﬁcantly
increasedboththeleveloftheﬁnalDAmetabolite,HVA(by
about 70%), and the rate of DA metabolism (by 50%). In
contrast to that, (S)-1MeTIQ signiﬁcantly depressed
DOPAC, HVA levels (by 60 and 40%, respectively), and
attenuated the rate of DA metabolism (by about 60%). On
the other hand, both the enantiomers increased the concen-
trations of DA and its extraneuronal metabolite, 3-MT in rat
striatum. In vivo microdialysis study has shown that repe-
ated but not acute administration of rotenone produced a
deep and signiﬁcant functional impairment of striatal DA
release. Both (R)- and (S)- stereospeciﬁc enantiomers of
1MeTIQ antagonized rotenone-induced suppression of DA
release; however, the effect of (R)-1MeTIQ was more
strongly expressed in microdialysis study. In conclusion, we
suggest that both chiral isomers of 1MeTIQ offer neuro-
protection against rotenone-induced disturbances in the
function of dopaminergic neurons and (R,S)-1MeTIQ will
be useful as a drug with marked neuroprotective activity in
the brain.
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Introduction
Parkinson’s disease (PD) is a neurological disorder, and the
most of its cases are idiopathic in nature even though in the
last few decades, many familial cases have been described
as well, and in some of them the underlying genetic defect
L. Antkiewicz-Michaluk (&)  A. Wa ˛sik  I. Roman ´ska 
J. Michaluk
Department of Neurochemistry, Institute of Pharmacology,
Polish Academy of Sciences, Sme ˛tna 12, 31-343 Krakow,
Poland
e-mail: antkiew@if-pan.krakow.pl
A. Bojarski
Department of Medicinal Chemistry, Institute of Pharmacology,
Polish Academy of Sciences, Sme ˛tna 12, 31-343 Krakow,
Poland
123
Neurotox Res (2011) 20:134–149
DOI 10.1007/s12640-010-9228-5has been identiﬁed. Parkinson‘s disease is caused by
mitochondrial complex I deﬁciency and neurodegeneration
of dopaminergic neurons in the substantia nigra (Schapira
et al. 1990). At present, it is believed that both genetic and
environmental factors are responsible for Parkinson‘s dis-
ease. Its classical cardinal signs include rigidity and bra-
dykinesia, resting tremor, and postural instability.
The environmental neurotoxins may largely contribute
to the development of this illness. One of the most famous
toxins of dopaminergic neurons is 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) which after injection to
humans and animals produces rapid, irreversible parkin-
sonism (Langston et al. 1983; Bankiewicz et al. 1986).
MPTP, acting through its metabolite, 1-methyl-4-
phenylpyridinium ion (MPP
?), induces degeneration of
dopaminergic neurons, predominantly in the substantia
nigra. It was believed that the main mechanism by which
MPP
? caused neuronal damage involved mitochondrial
dysfunction produced by the inhibition of mitochondrial
complex I activity that led to mitochondrial depolarization
and generation of reactive oxygen species (Nakamura et al.
2000). However, Lotharius and O’Malley (2000) indicated
that the generation of reactive oxygen species during the
oxidation of dopamine released by MPP
? was the main
consequence of MPP
?-induced neurotoxicity. MPTP has
frequently been used to provide an animal model of
Parkinson‘s disease (Gerlach and Riederer 1996).
More recently, it has been found that another, much more
frequently encountered environmental toxin, rotenone
may be used to produce a more realistic animal model of
Parkinson‘sdisease(Betarbetetal.2000).Rotenone,anatural
compound,isaclassicallipophilicinhibitorofmitochondrial
complex I (Gutman et al. 1970; Horgan et al. 1968), and is
selectively toxic to dopaminergic neurons (Marey-Semper
et al. 1993; Testa et al. 2005). Injected directly into brain
structures, rotenone acts similarly to MPTP (Heikkila et al.
1985). Rotenone is the only neurotoxin known today that
induces the formation of Lewy bodies, which are the most
characteristic histopathological feature of Parkinson’s dis-
ease (Betarbet et al. 2000). As in the case of MPTP, a defect
of mitochondrial function due to complex I inhibition was
postulated to be the cause of rotenone-induced neurode-
generation (Betarbet et al. 2000; Jenner 2001; Greenamyre
et al. 2001). Rotenone used in a high concentration also
causes dopamine release, as evidenced by microdialysis and
neurochemical data (Santiago et al. 1995; Thiffault et al.
2000), and this may also contribute to the degeneration of
dopaminergicneurons.Chronicadministrationofalowdose
of rotenone in rats reproduces most of the motor, neuro-
chemical, and pathological features of PD shown to be
attenuated by L-DOPA (Alam and Schmidt 2002).
In addition to the exogenous neurotoxins which have
been widely used as convenient and acceptable models for
the induction of experimental Parkinson‘s disease,
endogenous amines present in the human and animal brain,
such as salsolinol or 1-benzyl-1,2,3,4-tetrahydroisoquino-
line (1BnTIQ) and to a lesser extent 1,2,3,4-tetrahydro-
isoquinoline (TIQ) (Lorenc-Koci et al. 2000, 2004) may
participate in the pathogenesis of Parkinson‘s disease (Abe
et al. 2005; Antkiewicz-Michaluk et al. 2000a, b;
Antkiewicz-Michaluk and Vetulani 2001; Kotake et al.
1995, 1996; Nagatsu 1997; Niwa et al. 1987). However,
among them TIQ, and its close methyl derivative, 1-methyl-
1,2,3,4-tetrahydroisoquinoline (1MeTIQ) was found to be a
neuroprotective (Antkiewicz-Michaluk et al. 2006; Lorenc-
Kocietal.2000,2005;Kohnoetal.1986;Tasakietal.1991;
Yamakawa and Ohta 1999; Yamakawa et al. 1999) and an-
tiaddictive compound (Antkiewicz-Michaluk et al. 2005,
2007;Filipetal.2007;Wa ˛siketal.2007;Wro ´bel2005)with
special effects on dopamine metabolism (Antkiewicz-
Michaluk et al. 2001, 2006).
More recently, our experiments have shown a neuro-
protective effect of 1MeTIQ evidenced by the reduction of
rotenone-induced mortality and changes in dopamine
metabolism, and ﬁnally, by mitigation of dopamine
nigrostriatal neuron degeneration after rotenone injection
into the medial forebrain bundle (Antkiewicz-Michaluk
et al. 2003, 2004). It is important to mention that 1MeTIQ
is present in the human and rodent brain as a mixture of
stereospeciﬁc (R)- and (S)-1MeTIQ enantiomers. The
racemate, (R,S)-1MeTIQ has been found to restraint the
formation of 3,4-dihydroxyphenylacetic acid (DOPAC),
during dopamine metabolism and to shift the catabolism
toward the O-methylation route, while the neurotoxic
substances like: 1-benzyl-1,2,3,4-tetrahydroisoquinoline,
rotenone or MPTP produce the opposite effect
(Antkiewicz-Michaluk et al. 2001; Antkiewicz-Michaluk
and Vetulani 2001; Antkiewicz-Michaluk et al. 2003;
Lotharius and O’Malley 2000). In addition, (R,S)-1MeTIQ,
was shown to prevent MPTP-, 1BnTIQ- and rotenone-
induced behavioral and neurochemical abnormalities
(Antkiewicz-Michaluk et al. 2003, 2004; Kotake et al.
1995; Tasaki et al. 1991). Furthermore, it was demon-
strated that (R,S)-1MeTIQ was markedly depleted in the
parkinsonian human brain (Ohta et al. 1987). Thus, (R,S)-
1MeTIQ is considered to play an important role in the
prevention of neurotoxin-induced parkinsonism. However,
the question arises whether the chirality of 1MeTIQ affects
these phenomena, and which of these two enantiomers
expresses a neuroprotective activity. In addition, recent
regulatory guidelines have recommended the development
of single enantiomer of compounds that have or may have
clinical applications. This recommendation is based on the
idea that a single enantiomer may offer clinical advantages
over the racemate in terms of potency, efﬁcacy and toler-
ability. In order to address these problems, we decided to
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the (R)- and (S)-1MeTIQ in rotenone-treated rats. In the
last decade, it has been shown that systemic administration
of rotenone induces different patterns of dopamine system
abnormalities depending on the route of administration,
dose regimen used and the animal species.
In this study, we aim to show the ﬁrst signs of the
functional impairment of dopamine system produced by a
low dose (3 mg/kg) of repeated intraperitoneal rotenone
administration. For the estimation of the dopaminergic
system function, we used both ex vivo an in vivo bio-
chemical studies, and compared the effects of an acute and
multiple (three times) injection of rotenone on dopamine
metabolism and its in vivo release in rat striatum. It is
important to mention that such experimental design did not
produce yet the depletion of tissue dopamine concentration
in the striatum although, the function of dopamine neurons
was already disturbed. In addition, to record dynamic
behavior of rats we measured also locomotor activity using
automated locomotor activity boxes. Finally, we investi-
gated the possible neuroprotective role of optically active
1MeTIQ enantiomers: (R)- and (S)-1MeTIQ in the rote-
none-induced disturbances in the function of striatal
dopamine neurons.
Materials and Methods
Animals and Treatment
Behavioral tests were carried out on male Wistar (Charles
River) rats, of initial body weight 260–300 g (about
9 weeks old) kept under standard laboratory conditions,
eight to a large animal cage. The rats used for the micro-
dialysis study after surgery were housed for a couple of
days individually. All animals had free access to standard
laboratory food and tap water, and were maintained at
room temperature (22C) with natural day–night cycle. The
experiments were carried out between 09:00 and 16:00 h.
Control rats were treated with an appropriate solvent.
Acute and multiple rotenone injections were adminis-
tered subcutaneously (s.c.) in a low, 3 mg/kg dose, as a
suspension prepared in 1% Tween 80 solution by sonica-
tion. The (R)- and (S)-1MeTIQ enantiomers were dissolved
in 0.9% NaCl solution and administered in a dose of
50 mg/kg intraperitoneally (i.p.). In the combined groups,
(R)- and (S)-1MeTIQ enantiomers were administered only
once, 5 min before a single dose of rotenone or in the case
of repeated rotenone treatments just before the third
injection of rotenone. The dose of both (R)- and (S)-1Me-
TIQ enantiomers was chosen based upon their activity in
the in vivo functional and biochemical studies
(Antkiewicz-Michaluk et al. 2009; Wasik et al. 2009a, b).
All procedures were carried out in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were granted an approval from the
Bioethics Commission as compliant with Polish Law. All
the experimental procedures were approved by the Local
Bioethics Commission of the Institute of Pharmacology,
Polish Academy of Sciences in Krako ´w.
Drugs
Rotenone (Sigma, St. Louis, MO USA) was obtained
commercially. (R)- and (S)-enantiomers of 1-methyl-
1,2,3,4-tetrahydroisoquinoline (1MeTIQ), were synthe-
sized by Dr. Jan Boksa, Department of Drug Chemistry,
Institute of Pharmacology Polish Academy of Sciences,
Krakow, Poland. Purity of the compounds was veriﬁed by
measurement of the melting point, and homogeneity was
assessed on a chromatographic column. The stereochemi-
cal structures of the (R)- and (S)-1MeTIQ are shown in
Fig. 1.
Behavioral Tests
Locomotor Activity
The locomotor activity and rearing were examined using
actometers Opto-Varimex activity monitors (Columbus
Inst., USA) linked on line to an IBM-PC compatible
computer. Each cage (43 9 44 9 25 cm) was surrounded
with a 15 9 15 array of photocell beams located 3 cm
from the ﬂoor surface as reported previously (Filip et al.
2007). Interruptions of these photocell beams were counted
as a measure of horizontal-locomotor activity deﬁned as
the distance travelled (in cm). Each data expressed of unit
time (15 min).
The rats received rotenone in a dose of 3 mg/kg s.c.
acutely or for three consecutives days, the control group
was treated with the solvent. (R)- and (S)- 1MeTIQ enan-
tiomers (50 mg/kg i.p.) were administered acutely, and in
the combined groups 5 min before acute rotenone admin-
istration or just before the third rotenone injection. After-
ward, the animals were transferred to the experimental
cages, and after a 30-min adaptation the basic locomotor
Fig. 1 Chemical structure of (R)- and (S)-1-methyl-1,2,3,4-tetrahy-
droisoquinoline (1MeTIQ)
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123activity (travelled distance in cm) was recorded during
90 min. The results were analyzed using Auto-Track
Software Program (Columbus Instruments, USA). From
ﬁve to six animals per group were used in behavioral study.
After completion of the behavioral test, the rats were
decapitated (3 h after rotenone injection), and the striatum
was removed for further biochemical evaluation.
Biochemical Assays
Ex vivo Biochemical Studies—Dopamine Metabolism
in the Rat Striatum
At the end of the behavioral experiments, the rats were
killed by decapitation, and the striatum was dissected
immediately and the obtained tissue was frozen on solid
CO2 (-70C) and stored until used for biochemical
assay. Dopamine and its metabolites, the intraneuronal
metabolite, DOPAC; the extraneuronal-3-methoxytyramine
(3-MT); and the ﬁnal metabolite, homovanillic acid (HVA)
were assayed by means of high-performance liquid chro-
matography (HPLC) with electrochemical detection. The
chromatograph HP 1050 (Hewlett-Packard, USA) was
equipped with Hypersil columns BDS-C18 (4 9 100 mm,
3 lm). The tissue samples were weighed and homogenized
in an ice-cold 0.1 M perchloroacetic acid containing
0.05 mM ascorbic acid. After centrifugation (10,000 9 g,
5 min), the supernatants were ﬁltered through RC58
0.2-lm diameter of pore cellulose membranes (Bioanalyt-
ical Systems, West Lafayette, IN, USA). The mobile phase
consisted of 0.05 M citrate–phosphate buffer, pH 3.5,
0.1 mM EDTA, 1 mM sodium octyl sulfonate and 3.5%
methanol. The ﬂow rate was maintained at 1 ml/min.
Dopamine and its metabolites were quantiﬁed by peak area
comparisons with standards run on the day of analysis.
In vivo Dopamine Release in the Rat Striatum—a
Microdialysis Study
The rats were anesthetized with ketamine (75 mg/kg) and
xylazine (10 mg/kg) and secured in stereotaxic frame
(Stoelting, USA). Vertical microdialysis guides (Intrace-
rebral Guide Cannula with stylet; BAS Bioanalitical, USA)
were implanted in the striatum (STR) with the following
stereotaxic coordinates: A/P ?1.0, L/M ?2.5, and V/D
-3.5 mm from the bregma point and dura, respectively
(G. Paxinos and CH Watson).
On the seventh day after surgery, the microdialysis
probes were placed inside the guides, and next the striatum
was perfused with an artiﬁcial cerebrospinal ﬂuid (aCSF)
consisting of 140 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2,
1 mM MgCl2, 0.3 mM NaH2PO4, 1.7 mM Na2HPO4,p H
7.4 at a ﬂow rate of 1.5 ll/min with a microinfusion pump
(Stoelting, Illinois USA). The samples were collected from
freely moving rats at 20-min intervals after a 3-h wash-out
period. The rats received rotenone in a dose of 3 mg/kg s.c.
acutely or repeatedly (for 3 consecutives days), and the
control group was treated with the vehicle. The basal
samples were collected from ‘‘-60’’ to ‘‘0’’ (control sam-
ples), and in the case of repeated treatment of rotenone the
basal samples ‘‘-60’ to ‘‘0’’ were collected 24 h after the
second injection of rotenone just before the third its
injection in the point ‘‘0’’. (R)- and (S)- 1MeTIQ enantio-
mers (50 mg/kg i.p.) were administered acutely, and in the
combined groups together with acute rotenone adminis-
tration or just before the third rotenone injection (repeated
treatment). The dialysate was collected every 20 min up to
3 h. All probes were immediately frozen on solid CO2
(-70C) till used for biochemical assay.
Dopamine (DA) was assayed in dialysates (20 ll) using
HPLC with ESA Coulochem III elecrochemical detection
(USA). The chromatograph Dionex (Germany) was
equipped with Hypersil Gold columns C18 (3 9 150 mm,
3 lm). The mobile phase consisted of 0.05 M citrate–
phosphate buffer, pH 3.5, 0.1 mM EDTA, 1 mM sodium
octyl sulfonate and 3.5% methanol. The ﬂow rate was
maintained at 1 ml/min. The chromatographic data were
processed by ChemStation computer program and dopa-
mine was quantiﬁed by peak area comparisons with stan-
dard run on the day of analysis.
At the end of the experiments, brains were examined
histologically in frozen slices for veriﬁcation of probe
placement (Fig. 2). Six animals per group were used for
microdialysis study.
Fig. 2 The illustration of dialysis probe (4 mm) placement in the
striatum (according to the atlas of Paxinos and Watson [1986]).
Interaural 10.00 mm; Bregma 1.00 mm
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The results from behavioral studies were calculated by a
two-way analysis of variance (ANOVA) for repeated
measures, followed when appropriate by Duncan’s post-
hoc test. The results were considered statistically signiﬁ-
cant when P\0.05.
Ex vivo biochemical experiments were analyzed by
means of a two way-analysis of variance (ANOVA) fol-
lowed by Duncan’s post-hoc test when appropriate. The
results were considered statistically signiﬁcant when
P\0.05. The total catabolism rate for dopamine was
assessed from the ratio of the ﬁnal dopamine metabolite
concentration, homovanillic acid to dopamine concentra-
tion and expressed as the catabolic rate index ([HVA]/
[DA]) 9 100. The index of the oxidative dopamine
catabolism rate (MAO dependent) was expressed as
([DOPAC]/[DA]) 9 100, and the index of the O-methyl-
ation dopamine catabolism rate (COMT dependent) as
([3-MT]/[DA]) 9 100. The indices were calculated using
concentrations from individual tissue samples as described
before (Antkiewicz-Michaluk et al. 2001).
The results from microdialysis in vivo studies were
analyzed by means of a repeated one-way analysis of
variance (ANOVA) followed by Duncan’s post-hoc test
when appropriate. The results were compared to 100% of
basal line which is deﬁned as the mean concentration of
-60 to 0 time. The results were considered statistically
signiﬁcant when P\0.05.
Results
Behavioral Tests
Locomotor activity: the effect of (R)- and (S)-1MeTIQ
enantiomers.
Acute Rotenone
The two-way ANOVA for repeated measures has shown no
signiﬁcant effect of acute rotenone administration on the
locomotor activity (Fig. 3a, b) in rats. On the other hand,
the repeated two-way ANOVA revealed a signiﬁcant effect
of both, (R)- and (S)-1MeTIQ enantiomers on the rat
locomotor activity as follow: Treatment F1,19 = 15.52,
P\0.0002; F1,19 = 20.12, P\0.0002, respectively, and
Time F5,95 = 3.47, P\0.006; F5,95 = 3.54, P\0.005,
respectively (Fig. 3a, b). The effect of Time versus
Treatment of (S)-1MeTIQ enantiomer was also signiﬁcant
(F5,95 = 2.50, P\0.035). Post-hoc analysis indicated a
signiﬁcant elevation of the rat locomotor activity after both
(R)- and (S)-1MeTIQ enantiomer administration in naive
and in rotenone-treated rats (Fig. 3a, b).
Repeated Rotenone
The repeated (three consecutive days) administration of
rotenone similarly to the acute injection did not reveal a
signiﬁcant effect (a repeated two-way ANOVA) on the
locomotor activity (Fig. 4a, b). The two-way ANOVA for
repeated measures has shown a signiﬁcant effect of Treat-
ment by (R)- and (S)-1MeTIQ enantiomers (F2,18 = 7.55,
P\0.0041)andTime(F7,126 = 71.90,P\0.00001)onthe
rat locomotor activity. The effect of Time versus Treatment
was also signiﬁcant (F14,126 = 3.22, P\0.0002). As dem-
onstrated by post-hoc analysis, (R)- and (S)-1MeTIQ enan-
tiomers produced a signiﬁcant elevation of locomotor
activity both in naive and repeated rotenone-treated rats
(Fig. 4a, b).
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Fig. 3 Locomotor activity (horizontal activity) after a single admin-
istration of rotenone (3 mg/kg s.c.), (R)-and (S)-1MeTIQ enantio-
mers, and combined treatment in rat. a The effect of (R)-1MeTIQ
(50 mg/kg i.p.) enantiomer. b The effect of (S)-1MeTIQ (50 mg/kg
i.p.). The number of animals in a group n = 4–6. The data are
expressed as means ± S.E.M. * P\0.05, ** P\0.01 to Control
group;
? P\0.05,
?? P\0.01 to Rotenone-treated group (two-way
analyses of variance ANOVA for repeated measures, followed when
appropriate by Duncan’s post-hoc test)
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Ex vivo Studies
The analysis showed a general Treatment effects for acute
and repeated Rotenone (3 mg/kg s.c.), 1MeTIQ (R)-and
(S)-enantiomers (50 mg/kg i.p.), and Interaction between
Rotenone 9 1MeTIQ enantiomers on the concentration of
DA, and its metabolites: DOPAC, 3-MT, HVA. In addition,
the dopamine catabolism rate was presented as the fol-
lowing ratios: total ([HVA]/[DA]); oxidation ([DOPAC/
[DA]) and O-methylation ([3-MT/[DA]) in the rat striatum,
and demonstrated by two-way ANOVA analysis of vari-
ance (Tables 1, Table 2).
Acute Rotenone (Table 1)
A two-way ANOVA revealed a non-signiﬁcant effects of
Treatment 1 with Rotenone and Interaction of Rote-
none 9 1MeTIQ enantiomers on all investigated dopami-
nergic parameters. On the other hand, Treatment 2 with
1MeTIQ enantiomers has shown a signiﬁcant effects on the
concentration of DOPAC (F2,20 = 241.58, P\0.00001),
3-MT (F2,20 = 22.16, P\0.00005), HVA (F2,20 = 98.97,
P\0.00001), and catabolic ratios: total (F2,20 = 96.31,
P\0.00001), oxidation (F2,20 = 242.35, P\0.00001),
O-methylation (F2,20 = 32.75, P\0.00001) in the rat
striatum (Table 1). A subsequent Duncan‘s post-hoc anal-
ysis revealed that concentration of the intraneuronal DA
metabolite, DOPAC was considerably decreased in the
(S)-1MeTIQ and Rotenone ? (S)-1MeTIQ-treated groups
(by about 70% of the control, P\0.01). The content of the
extraneuronal DA metabolite, 3-MT was signiﬁcantly ele-
vated in (R)- and (S)-1MeTIQ-treated groups as well as in
jointed treatments of 1MeTIQ enantiomers with Rotenone
(by about 40–85% of the control, P\0.01). The level of
the ﬁnal DA metabolite, HVA was markedly elevated in
(R)-1MeTIQ group (by about 50% of the control,
P\0.01) and in combined (R)-1MeTIQ ? Rotenone
group (by 70% of the control, P\0.01). In contrast to
that, in (S)-1MeTIQ-treated group as well as in joined
(S)-1MeTIQ ? Rotenone group the concentration of HVA
was strongly decreased (by about 50% of the control,
P\0.01).
A two-way ANOVA demonstrated a signiﬁcant effect
(F2,20 = 96.31, P\0.00001), of Treatment 2 with
1MeTIQ enantiomers on the total DA metabolism rate
expressed as the ratio of ([HVA]/[DA]) in the striatum. A
post-hoc analysis revealed a signiﬁcantly increased DA
metabolism rate in (R)-1MeTIQ and (R)-1MeTIQ ?
Rotenone-treated groups (by about 40% of the control,
P\0.01). In contrast to that, in (S)-1MeTIQ-treated
groups, an appreciably decreased DA metabolism rate (by
about 40% of the control, P\0.01) was observed. The rate
of the oxidation pathway of DA catabolism expressed as
([DOPAC]/[DA]) was strongly decreased in (S)-1MeTIQ-
treated group (by about 75% of the control value) whereas
in (R)-1MeTIQ-treated groups the effect was weak (a
decrease by about 15% of the control, P\0.05). The rate
of O-methylation pathway of DA catabolism was signiﬁ-
cantly elevated ( from 25% P\0.05 to 70% P\0.01 of
the control) in all groups treated with 1MeTIQ enantiomers
(Table 1).
Repeated Rotenone (Table 2)
A two-way ANOVA demonstrated a non-signiﬁcant effects
of Treatment 1 with repeated Rotenone and Interaction of
repeated Rotenone 9 1MeTIQ enantiomers on the con-
centration of DA and its metabolites in the rat striatum.
Treatment 1 with repeated Rotenone revealed only a sig-
niﬁcant effect on the DA O-methylation rate ([3-MT]/
[DA]) (F1,22 = 16.85, P\0.000467). On the other hand,
Treatment 2 with 1MeTIQ enantiomers has shown a
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123signiﬁcant effects on all investigated biochemical param-
eters: concentration of DA (F2,22 = 3.75, P\0.039758);
DOPAC (F2,22 = 41.51, P\0.00001); 3-MT (F2,22 =
26.87, P\0.00001); HVA (F2,22 = 47.07, P\0.00001);
and the catabolic ratios: total ([HVA]/[DA]) (F2,22 =
144.00, P\0.00001), oxidation ([DOPAC]/[DA]) (F2,22
= 199.95, P\0.00001), O-methylation ([3-MT]/[DA])
(F2,22 = 50.805, P\0.00001) in the rat striatum
(Table 2). A subsequent Duncan‘s post-hoc analysis
revealed that concentration of the intraneuronal DA was
considerably increased in the (R)- and (S)-1MeTIQ-treated
groups (by about 30% of the control, P\0.05) and in
Rotenone ? (S)-1MeTIQ-treated group (by about 27%
of the control, P\0.05). The content of the intraneuronal
DA metabolite, DOPAC was signiﬁcantly elevated by
(R)-1MeTIQ-treated group (by 30% of the control,
P\0.026), and opposite to that DOPAC was decreased in
(S)-1MeTIQ and Rotenone ? (S)-1MeTIQ-treated groups
(by about 50% to 60% of the control, respectively,
P\0.001). The content of the extraneuronal DA metab-
olite, 3-MT was signiﬁcantly depressed (by about 20%,
P\0.05) in repeated Rotenone-treated group, and oppo-
site to that elevated in (R)- and (S)-1MeTIQ-treated groups
as well as in jointed treatments of 1MeTIQ enantiomers
with Rotenone (by about 25% to 130% of the control,
P\0.004). The level of the ﬁnal DA metabolite, HVA
was markedly elevated in (R)-1MeTIQ group (by about
130% of the control, P\0.0001) and in combined (R)-
1MeTIQ ? Rotenone group (by 80% of the control,
P\0.001). In contrast to that, in (S)-1MeTIQ–treated
group as well as in joined Rotenone ? (S)-1MeTIQ-treated
group the concentration of HVA was decreased (by about
45% of the control, P\0.05) (Table 2).
A two-way ANOVA demonstrated a signiﬁcant effect
(F2,22 = 144, P\0.00001) of 1MeTIQ enantiomer treat-
ments (Treatment 2) but not repeated Rotenone treatment
(Treatment 1) on the total DA metabolism rate expressed as
the ratio of ([HVA]/[DA]) in the striatum. A post-hoc
analysis revealed a signiﬁcantly increased DA metabolism
rate in (R)-1MeTIQ and Rotenone ? (R)-1MeTIQ-treated
groups (by about 70% of the control, P\0.0001). In
contrast to that, in (S)-1MeTIQ-treated groups an appre-
ciably decreased DA metabolism rate (by from about 45%
to 60% of the control, P\0.0005) was observed. The rate
of the oxidation pathway of DA catabolism expressed as
([DOPAC]/[DA]) was strongly decreased in (S)-1MeTIQ-
treated groups (by about 65% of the control value,
P\0.0005) whereas in (R)-1MeTIQ-treated groups it was
not changed. A two-way ANOVA demonstrated a signiﬁ-
cant effect (F1,22 = 16.848, P\0.00046) of repeated
Rotenone treatment (Treatment 1) as well as 1MeTIQ
enantiomers treatments (Treatment 2) (F2/22 = 50.805,
P\0.0001) on the rate of O-methylation pathway of DA
catabolism in the rat striatum. A post-hoc analysis revealed
that repeated Rotenone treatment produced a signiﬁcant
decrease the rate of DA O-methylation (by about 25% of
the control, P\0.05). In contrast to that both 1MeTIQ
enantiomers increased the rate of DA O-methylation (by
about 40% to 80% of the control, P\0.01) and com-
pletely antagonized the effect of Rotenone (Table 2).
In Vivo Dopamine Release in the Rat Striatum—a
Microdialysis Study
Acute Rotenone
Mean control basal extracellular concentration of dopamine
in dialysates from the striatum was about 9.8 ± 1.3 (pg/
20 ll). A repeated-measures analysis of variance revealed
not signiﬁcant effect of Treatment (with acute Rotenone,
(R)-1MeTIQ and combined group Rotenone ? (R)-1Me-
TIQ) but signiﬁcant effect of Time (F2,108 = 4.778,
P\0.00001) and interaction of Time versus Treatment
(F2,108 = 2.139, P\0.0043). A post-hoc analysis demon-
strated not signiﬁcant effect of Rotenone and (R)-1MeTIQ
enantiomer, and only a slight but signiﬁcant increase of
dopamine release in the striatum in the combined Rote-
none ? (R)-1MeTIQ-treated group (Fig. 5a). In case of
(S)-1MeTIQ enantiomer, a repeated-measures analysis of
variance has shown a signiﬁcant effect of Treatment (with
acute Rotenone, (S)-1MeTIQ and co-administered group
Rotenone ? (S)-1MeTIQ) (F2,108 = 6.870, P\0.0154)
as well as Time (F2,108 = 16.609, P\0.00001) and
interaction of Time versus Treatment (F2,108 = 4.127,
P\0.00001). A post-hoc Duncan’s test demonstrated that
(S)-1MeTIQ enantiomer-treated group as well as joined
Rotenone ? (S)-1MeTIQ group showed a signiﬁcantly
increased (about 230%, P\0.01) dopamine release in the
ratstriatum.Oppositetothat,acuteRotenoneadministration
did not affect dopamine release in the striatum (Fig. 5b).
Repeated Rotenone
The comparison of the effects of the acute and repeated
(3 days) Rotenone administration on dopamine release in
the rat striatum has shown a pronounced difference between
them. A repeated-measures analysis of variance revealed a
signiﬁcant effect of Treatments (Saline-treated group—
Control, Acute Rotenone and Repeated Rotenone groups)
(F2,108 = 7.619, P\0.00001). A post-hoc test indicated
that repeated but not acute Rotenone administration pro-
duced a huge decrease in dopamine concentration (about
65–75% of Control group, P\0.01) in extracellular area of
the rat striatum (Fig. 6). Both (R)- and (S)-1MeTIQ enan-
tiomers were able to antagonize rotenone-induced sup-
pression of dopamine release as it is demonstrated in Fig. 7.
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123A repeated-measures analysis of variance revealed a sig-
niﬁcant effect of Treatment (F3,144 = 4.402, P\0.026),
Time (F3,144 = 7.020, P\0.00001) and interaction Time
versusTreatment(F3,144 = 2.835,P\0.00001).A post-hoc
Duncan’s test demonstrated that (R)-1MeTIQ enantio-
mer acted more strongly than (S)-1MeTIQ and not only
reversed the Rotenone-produced depletion of the dopamine
concentration to Control value but markedly increased
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123dopamine in the extracellular area of the rat striatum
(Fig. 7).
Discussion
It is currently believed that Parkinson‘s disease is caused
not only by genetic, but also, to a large extent, by envi-
ronmental factors, of which herbicides may play an
important, though not exclusive role (Gorell et al. 1998).
Rotenone was described as a neurotoxic agent, inducing in
experimental animals a parkinsonian-like syndrome
(Betarbet et al. 2000). Since rotenone is widely used as a
pesticide in agriculture and to protect household pets
against insect parasites, its neurotoxic properties may pose
a threat to farmers and pet owners. Two lines of reasoning
support the role of rotenone. Firstly, both in hereditary and
spontaneous Parkinson‘s disease the activity of mitochon-
drial complex I is decreased, and rotenone is a potent
inhibitor of this complex (Horgan et al. 1968; Gutman et al.
1970; Swerdlow et al. 1996). Secondly, oxidative damage
is strongly implicated in the neurodegeneration of dopa-
minergic neurons (Lamensdorf et al. 2000) and, as shown
by us previously, rotenone potently activates dopamine
metabolism along the oxidative pathway (Antkiewicz-
Michaluk and Vetulani 2001). The formerly published data
have demonstrated that the endogenous substance, race-
mate 1MeTIQ, a mixture of two (R)- and (S)- enantiomers,
protects animals against rotenone-induced mortality and
neurodegeneration in the extrapyramidal structures
produced by its peripheral and intracerebral injection
(Antkiewicz-Michaluk et al. 2003, 2004). A part of the
observed behavioral abnormalities may be explained by
the action of rotenone on the dopaminergic system. The
repeated but not acute rotenone administration (7 days), in
a dose of 12 mg/kg s.c. was found to strongly increase
dopamine metabolism, as measured by the increase in
concentration of the intraneuronal dopamine metabolite,
DOPAC, and the ﬁnal metabolite, HVA, and interestingly,
at the same time it depressed the concentration of the
extracellular dopamine metabolite, 3-MT (Antkiewicz-
Michaluk et al. 2003). Such neurochemical changes do
not imply a direct neurotoxic action, but the shift in
dopamine catabolism toward the oxidative pathway, gen-
erating free radicals, which may lead to neurodegeneration
(Antkiewicz-Michaluk et al. 2001; Miller et al. 1996).
These changes were effectively counteracted by the
administration of racemate (R,S)-1MeTIQ before each
dose of rotenone (Antkiewicz-Michaluk et al. 2003). In
another model of neurotoxicity produced by malonate
(Green and Greenmyre 1995; Zeevalk et al. 1995), a
reversible inhibitor of the mitochondrial enzyme succinate
dehydrogenase a close derivative of 1MeTIQ, 1,2,3,4-tet-
rahydroisoquinoline (TIQ) expressed also neuroprotective
activity (Lorenc-Koci et al. 2005). A large body of evi-
dence from in vivo and in vitro studies show that the
damage of dopamine neurons due to rotenone- and mal-
onate-induced impairment of energy metabolism is a con-
sequence of mechanisms which involve the generation of
free radicals, toxicity of dopamine, and secondary
0
50
100
150
200
250
-60 -40 -20 0 20 40 60 80 100 120 140 160 180
Time (min)
%
 
o
f
 
B
a
s
a
l
 
l
e
v
e
l
Control 3xRotenone
3xRotenone+(R )-1MeTIQ 3xRotenone+(S)-1MeTIQ Dopamine
* * * * *
* ***
*
* * * * *
++ +
++ ++
+
++
++ +
Fig. 7 Microdialysis study: The effect of (R)- and (S)-1MeTIQ
enantiomers on the suppression of dopamine release in rat striatum
induced by repeated (during 3 consecutives days) rotenone (3 mg/
kg s.c.) administration. Arrow in the point ‘‘0’’ indicates the drug
injections: Control (saline group); 3 9 Rotenone (a third injection of
rotenone 3 mg/kg s.c. ? Saline i.p.); 3 9 Rotenone ? R-1MeTIQ (a
third injection of rotenone 3 mg/kg s.c. ? (R)-1MeTIQ 50 mg/kg
i.p.); 3 9 Rotenone ? S-1MeTIQ (a third injection of rotenone 3 mg/
kg s.c. ? (S)-1MeTIQ 50 mg/kg i.p.). The number of animals in a
group n = 4. The data are expressed as means ± S.E.M. * P\0.05,
** P\0.01 versus Control value;
? P\0.05,
?? P\0.01 versus
3 9 Rotenone-treated group (one-way analyses of variance ANOVA
followed by Duncan’s post-hoc test when appropriate)
144 Neurotox Res (2011) 20:134–149
123excitotoxicity (Antkiewicz-Michaluk et al. 2003, 2004;
Beal et al. 1993; Ferger et al. 1999; Green and Greenmyre
1995; Green et al. 1993; Moy et al. 2000). Consistent with
this, endogenous tetrahydroisoquinolines: TIQ and 1Me-
TIQ which display free radical scavenging properties as
well as MAO inhibitory properties that attenuate dopamine
catabolism and are partial NMDA receptor antagonists
preventing the activation of this receptor, provide effective
protection from these neurotoxins (Antkiewicz-Michaluk
et al. 2006; Lorenc-Koci et al. 2005; Patsenka and
Antkiewicz-Michaluk 2004).
In this article, we chose a four times lower dose of
rotenone (3 mg/kg) than was used by us previously, which
in this study did not affect tissue concentration of dopa-
mine, its metabolism and the rate of oxidative pathway in
the rat striatum. However, the concentration of 3-MT and
the rate of dopamine O-methylation was signiﬁcantly
depressed after repeated administration of rotenone, and
these effects of rotenone were completely antagonized by
both stereospeciﬁc enantiomers of 1MeTIQ (Table 2). The
question arises: whether dopaminergic neuron function
evaluated by in vivo dopamine release would be affected in
such experimental conditions? The results from our paper
demonstrated that ﬁrstly, thrice rotenone administration in
a low dose produced a considerable, signiﬁcant impairment
of the striatal dopamine release in vivo. Secondly, both (R)-
and (S)- stereospeciﬁc enantiomers of 1MeTIQ, displayed a
protective action against the rotenone-induced behavioral
and specially neurochemical disturbances. However, it
should be mention that rotenone in this investigated low
dose depressed slightly but not signiﬁcantly even after
repated administration a basic locomotor activity in rats
(Figs. 3a, b, 4a, b). In fact, it should be taken into account
that basic locomotor activity of control group was low, and
in such case it would be difﬁcult for any treatment makes it
signiﬁcant lower (Wasik et al. 2009a, b). Generally, the
results from behavioral and neurochemical in vivo micro-
dialysis studies have shown that neuroprotection offered by
1MeTIQ is not stereospeciﬁc and, its enantiomers (R)- and
(S)-1MeTIQ which are both present in the brain produced
similar to racemate effect as shown previously
(Antkiewicz-Michaluk et al. 2003, 2004) protect dopamine
neurons against rotenone-induced impairment of its func-
tion in the rat brain. In addition, the in vivo microdialysis
study demonstrated that (R)-enantiomer acted more
strongly than (S)-1MeTIQ, and additionally, it not only
prevented the rotenone-induced fall of extracellular dopa-
mine level but even increased it above the control
concentration.
On the other hand, the biochemical studies obtained
from striatal tissue are in agreement with the previous
published data (Antkiewicz-Michaluk et al. 2009; Wasik
et al. 2009a, b) and clearly demonstrated that (R)- and
(S)-1MeTIQ enantiomers differently affected the dopamine
metabolism rate and its catabolic pathways in the striatum
(Tables 1, 2). (R)-Enantiomer activated dopamine system
and signiﬁcantly increased all metabolic dopamine
parameters: its metabolic rate and the concentration of
dopamine and its metabolites. In contrast to (R)-enantio-
mer, (S)-1MeTIQ behaved as an MAO inhibitor in neuro-
chemical studies, and decreased the dopamine metabolic
rate as well as DOPAC and HVA levels but increased
3-MT, an extraneuronal metabolite of dopamine in the rat
striatum. In addition, the data has shown that (S)-1MeTIQ
behaved similarly to the racemate (R,S)-1MeTIQ however,
its neurochemical effect was even stronger (Antkiewicz-
Michaluk et al. 2001; Antkiewicz-Michaluk et al. 2004).
Taken together, it looks that both enantiomers activated
dopamine system: (R)-1MeTIQ by increasing dopamine
metabolism, (S)-1MeTIQ by inhibition of dopamine
catabolism. It is also important to mention that in contrast
to DOPAC and HVA levels, both stereospecif enantiomers
affected the concentration of dopamine and its extraneu-
ronal metabolite, 3-MT in the same direction signiﬁcantly
increasing their levels. It is important to mention that
pronounced increase of dopamine O-methylation along
COMT-dependent catabolic pathway may offers neuro-
protection in contrast to dopamine oxidation directly con-
nected with free radical production (Antkiewicz-Michaluk
et al. 2001; Miller et al. 1996). It was also demonstrated by
other authors that increasing of 3-MT in the process of
dopamine O-methylation has the function of protecting
against oxidative stress (Miller et al. 1996). Our present
data have shown that repeated treatment of rotenone sig-
niﬁcantly depressed both the rate of dopamine O-methyl-
ation as 3-MT concentration in rat striatum, and this effect
was completely antagonized by both 1MeTIQ enantiomers
(Table 2). In that light we suggest that (R)- and (S)- ste-
reospeciﬁc enantiomers of 1MeTIQ may offer neuropro-
tection. Besides, 3-MT is considered to be the most reliable
indicator of dopamine release into the synaptic cleft (Egan
et al. 1991; Karoum et al. 1994), and its rise after (R)- and
(S)-1MeTIQ administration, observed in this study, indi-
cates the increase in dopamine release into the extraneu-
ronal space. In fact, these ex vivo biochemical data are in a
good agreement with in vivo microdialysis experiments
which indicate that the administration of both enantiomers,
however, in greater degree (S)-1MeTIQ produced an
increase of extracellular dopamine concentration in the rat
striatum (Fig. 5a, b). In addition, behavioral data (a loco-
motor activity) also conﬁrm a slight stimulatory effect of
(R)- and (S)-enantiomers on dopaminergic system. In
control as well as in rotenone-treated rats, the administra-
tion of both stereo-enantiomers signiﬁcantly increased the
distance of walking (Figs. 3a, b, 4a, b). However, Abe et al.
(2001) have demonstrated in C57BL/6 N mice that
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a crucial role in protection against TIQ-induced parkin-
sonism. In our study, not only (R)-1MeTIQ but also
(S)-enantiomer antagonized the behavioral and neurochemi-
cal effects of repeated rotenone administration in the rat. Such
discrepancy concerning neuroprotective effects of stereo-
isomers of 1MeTIQ between our study and Abe et al.
(2001) results may be connected with distinct experimental
protocols which differed at least in animal species (rat,
mouse) and substances producing Parkinson‘s disease-like
symptoms (rotenone, TIQ). Anyhow, Alam and Schmidt
(2002) demonstrated also that rotenone in a similar low
dose 2.5 mg/kg but in contrast to us administered for a long
period of time (2 months) caused dopamine depletion in
the striatum and prefrontal cortex of the rat. In our hands, a
low dose of rotenone administered only three times sig-
niﬁcantly depressed the concentration of the striatal 3-MT.
As mention above, 3-MT is the most reliable biochemical
indicator of dopamine release into the synaptic cleft (Egan
et al. 1991), and its fall may suggest outset of irregularities
in function of dopamine neurons. In fact, in vivo micro-
dialysis studies presented in this article conﬁrmed the
above suggestion and demonstrated a pronounced decrease
in dopamine release in the striatum after repeated but not
acute rotenone administration (Fig. 7). These in vivo
results have shown for the ﬁrst time the initial, important
signs of rotenone functional neurotoxicity leading to a fall
of the striatal dopamine release. The demonstration in this
article of inhibition of the striatal dopamine release by
rotenone provides a unifying explanation for the motor
deﬁcits that can accompany rotenone exposure, even when
nigrostriatal degeneration is minimal. The question arises
as to what could be a molecular mechanism of action for
that rotenone effect. As it was already well established,
synaptic dopamine homeostasis is primarily controlled via
two presynaptic regulatory mechanisms, dopamine D2
receptor and dopamine transporter (DAT). Dopamine D2/3
receptors directly mediate dopamine synthesis and release
by being associated with DAT and regulate also DAT
function, linking dopamine release and reuptake to a
common mechanism (Campiani et al. 2003; Chen et al.
2009; Kebabian and Calne 1979; Le Foll et al. 2000; Shi
2009). Rotenone causes impairment of mitochondrial
respiratory enzyme function and reactive oxygen species
(ROS) generation but does not affect directly D2/3 dopa-
mine receptors or DAT function (Bowton et al. 2010).
However, in vitro studies focused on a real-time dopamine
release monitoring with carbon–ﬁber microelectrodes in
guinea pig striatal slices have shown that partial mito-
chondrial inhibition induced by a low, nanomolar con-
centrations of rotenone causes striatal dopamine release
suppression via hydrogen peroxide (H2O2) generation and
consequent activation of ATP-sensitive K ? channels (Bao
et al. 2005). In fact, KATP channels are important structures
in the regulation of dopamine release in the striatum and
dopaminergic neuron activity in the substantia nigra, and
its stimulation inhibits dopamine release (Avshalumov and
Rice 2003; Avshalumov et al. 2005). Moreover, KATP
channel opening mediates the physiological responses of
dopamine neurons to nanomolar concentrations of rotenone
(Liss et al. 1999). It has been recently also reported that
rotenone activates microglia, which then release superox-
ide (O2
-) through the action of NADPH oxidation enzyme,
thus exacerbating dopamine neurotoxicity (Gao et al. 2002;
Wang et al. 2005). Taken together, in vivo results of our
study are in a good agreement with those presented above
in vitro experiments and indicate that rotenone in a low
concentration causes an appreciable decline in the striatal
dopamine release which would further enhance dopamine-
dependent motor deﬁcits even in the absence of dopamine
fall in the nigrostriatal pathway. In this study, in vivo
microdialysis analysis has shown that the rotenone-induced
suppression of the striatal dopamine release was com-
pletely reversed by a single injection of both stereo-
enantiomers of 1MeTIQ: (R)- and (S)-1MeTIQ. As
demonstrated in the earlier articles, the most evident neu-
roprotective action among tetrahydroisoquinolines was
described for racemate, (R,S)-1MeTIQ (Tasaki et al. 1991;
Antkiewicz-Michaluk 2004; Antkiewicz-Michaluk et al.
2003, 2006), the compound that shows an interesting
pharmacological proﬁle and possibly plays the role of a
natural agent protecting the brain against Parkinson’s dis-
ease. (R,S)-1MeTIQ was demonstrated to act as an anti-
dopaminergic agent in the functional studies (Antkiewicz-
Michaluk et al. 2000a, b; Antkiewicz-Michaluk and
Vetulani 2001), but in contrast to typical neuroleptics, it
did not induce catalepsy in animals at all. Moreover, it
inhibited apomorphine-induced hyperactivity at doses at
which had no effect on spontaneous locomotor activity of
rats (Antkiewicz-Michaluk et al. 2001). An additional
ﬁnding, which may shed some light on the mechanism of
action of racemate, is the observation that (R,S)-1MeTIQ
displaces agonists (dopamine, apomorphine) but not
antagonists (spiperon) of dopamine receptor from their
binding sites (Antkiewicz-Michaluk et al. 2007). This
suggests that the racemate, (R,S)-1MeTIQ has an afﬁnity
for the agonistic (active) conformation of dopamine
receptors and expresses the effects which are characteristic
for dopamine partial agonists. We also previously found for
(R,S)-1MeTIQ, that its structure inhibited free radical
generation in an abiotic system, and diminished the indices
of glutamate-induced neurotoxicity (caspase-3 activity,
lactate dehydrogenase release) in mouse embryonic
primary cell cultures (Antkiewicz-Michaluk et al. 2006)
what would be also specially important for a possi-
ble explanation of neuroprotective activity of its (R)- and
146 Neurotox Res (2011) 20:134–149
123(S)- enantiomers. The present biochemical data addition-
ally have shown that (R)- and (S)- stereospeciﬁc enantio-
mers of 1MeTIQ in contrast to rotenone signiﬁcantly
increased dopamine O-methylation process and its product,
3-MT which has a pronounced protecting function against
oxidative stress (Miller et al. 1996). In that light we suggest
that neuroprotection may be offered by both stereospeciﬁc
enantiomers of 1MeTIQ.
In conclusion, this article has shown in ex vivo and in
vivo experiments for the ﬁrst time the neurochemical signs
of rotenone-induced impairment of striatal dopamine
function. An appreciable decline similar to the rate of
dopamine O-methylation and striatal dopamine release was
observed even in the absence of dopamine fall in the
nigrostriatal pathway. The results also clearly demonstrate
that neuroprotective activity of 1MeTIQ is connected with
both, (R)-and (S)-stereospecifc enantiomers which exhibit
antagonism to rotenone-produced suppresion of dopamine
O-methylation as well as dopamine release in rat striatum.
In that light, we may suggest that 1MeTIQ will be useful as
a drug with marked neuroprotective activity in the brain.
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